

**Table S2. Comparison of patient demographics and outcomes by mode of presentation for women with high grade serous ovarian cancer**

|   | <b>Fast-track pathway<br/>N=119</b> | <b>Emergency<br/>N=7</b> | <b>Other outpatients<br/>N=27</b> |
|---|-------------------------------------|--------------------------|-----------------------------------|
| <b>Age, years*</b><br>mean (S.D), p=0.031     | 65.0 (10.1)                         | 55 (16.1)                | 66.7 (10.2)                       |
| <b>Stage**</b><br>n (%), p=0.459              |                                     |                          |                                   |
| <b>Early stage</b>                            |                                     |                          |                                   |
| 1   | 12 (10.1)                           | 2 (28.6)                 | 2 (7.4)                           |
| 2   | 18 (15.1)                           | 0 (0.0)                  | 4 (14.8)                          |
| <b>Late stage</b>                             |                                     |                          |                                   |
| 3A  | 16 (13.5)                           | 1 (14.3)                 | 1 (3.7)                           |
| 3B  | 11 (9.2)                            | 0 (0.0)                  | 0 (0.0)                           |
| 3C  | 48 (40.3)                           | 1 (14.3)                 | 15 (55.6)                         |
| 4A  | 7 (5.9)                             | 0 (0.0)                  | 1 (3.7)                           |
| 4B  | 4 (3.4)                             | 2 (28.6)                 | 2 (7.4)                           |
| Not available                                 | 3 (2.5)                             | 1 (14.3)                 | 2 (7.4)                           |
| <b>Performance status**</b><br>n (%), P=0.611 |                                     |                          |                                   |
| 0   | 90 (75.6)                           | 4 (57.1)                 | 22 (81.5)                         |
| 1   | 22 (18.5)                           | 3 (42.9)                 | 2 (7.4)                           |
| 2   | 6 (5.0)                             | 0 (0.0)                  | 1 (3.7)                           |
| 3   | 0 (0.0)                             | 0 (0.0)                  | 1 (3.7)                           |
| Not available                                 | 1 (0.9)                             | 0 (0.0)                  | 1 (3.7)                           |
| <b>Cytoreduction rate**</b><br>n (%), P=0.920 |                                     |                          |                                   |
| Complete                                      | 73 (61.3)                           | 4 (57.1)                 | 18 (66.7)                         |
| Residual <1cm                                 | 18 (15.1)                           | 1 (14.3)                 | 3 (11.1)                          |
| Residual ≥1cm                                 | 2 (1.7)                             | 0 (0.0)                  | 2 (7.4)                           |
| Inoperable                                    | 9 (7.6)                             | 0 (0.0)                  | 2 (7.4)                           |
| Not available                                 | 17 (14.3)                           | 2 (28.6)                 | 2 (7.4)                           |

\* The ANOVA one-way test was used to calculate the p-value

\*\*The Kruskal-Wallis H test was used to calculate the p-value